N-{3-Chloro-4-[(3-Fluorobenzyl)Oxy]Phenyl}-6-[5-({[2-(Methylsulfonyl)Ethyl]Amino}Methyl)Furan-2-Yl]Quinazolin-4-Amine Benzenesulfonate Hydrate (1:2:1)

This is an organic compound named N- {3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl} -6- [5- ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2-yl] quinazoline-4-aminobenzenesulfonate monohydrate (1:2:1).
According to its naming, this compound has a complex structure. With quinazoline as the core parent ring, there is a phenyl group containing a specific substituent at the 4-position, specifically 3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl; the 6-position is connected with a substituent containing a furan ring, which is in turn connected with {[2 - (methylsulfonyl) ethyl] amino} methyl. And this compound is salted with benzenesulfonic acid in a ratio of 1:2, with a molecule of crystal water, showing a structural ratio of 1:2:1.
Quinazoline ring is a common structural unit in the field of organic synthesis, and many bioactive molecules contain this ring. In this product, various substituents connected by quinazoline ring may have important effects on their physical and chemical properties, especially biological activities. For example, the substitution of 3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl may affect the lipophilicity and electron cloud distribution of compounds; while the 6-position furan ring and linked substituents may be related to the interaction of specific biological targets. The formation of benzene sulfonate, or the improvement of the solubility and other properties of the compound, the existence of crystalline water, or its stability, crystal form, etc.

This drug is named N- {3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl} -6- [5- ({[2- (methylsulfonyl) ethyl] amino} methyl) furan-2-yl] quinazoline-4-aminobenzenesulfonate monohydrate (1:2:1). Its main uses are as follows:
This compound may be a new type of synthetic drug. In the field of pharmaceutical research and development, in-depth study of it can reveal its pharmacological activity and mechanism of action, and is expected to be developed into an innovative drug for the treatment of specific diseases. Due to its structural characteristics, it has specific affinity and activity for certain receptors or enzymes, which can regulate physiological processes in organisms and have potential value in the treatment of many diseases such as anti-tumor, anti-inflammatory, anti-cardiovascular disease, etc. Researchers can use the study of its mechanism of action and efficacy to explore new therapeutic targets and strategies.
From the perspective of pharmacochemistry, the structural modification and optimization of this compound can improve drug properties, such as improving solubility, stability and bioavailability, and provide ideas and directions for the design and development of new drugs. Under the development of precision medicine, if this compound has targeted efficacy for specific diseases and specific populations, it can become a key drug for personalized treatment plans.

To prepare N- {3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl} -6 - [5 - ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2 - yl] quinazoline-4 -amine benzenesulfonate monohydrate (1:2:1), the method is as follows:
First, various raw materials need to be prepared, such as phenyl, furan and quinazoline-related compounds containing specific substituents, and also the water required for the formation of benzenesulfonic acid and an appropriate amount of hydrate. In a clean reactor, the reactant containing 3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl is mixed with the substance containing 6-[ 5- ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2-yl] quinazoline-4-amine in a specific ratio with precise measurement. This mixing process needs to be carried out slowly under gentle stirring to ensure that the two are uniformly blended.
Then, at a suitable temperature environment, slowly add benzenesulfonic acid to the above mixture. This temperature needs to be strictly controlled. Too high or too low may affect the purity and yield of the product. After adding, continue to stir to make the reaction fully proceed. During this period, pay close attention to the changes in the reaction system, such as the characterization of color, temperature and degree of reaction.
When the reaction is approaching completion, the resulting mixture is properly disposed. The solid product can be separated by filtration. Then, the solid product is washed with an appropriate amount of solvent to remove impurities. After washing, the product is placed in a specific dry environment to form N- {3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl} -6 - [5 - ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2-yl] quinazoline-4-aminobenzenesulfonate monohydrate (1:2:1) containing a specific proportion of hydrate. The whole process requires fine operation and attention to the control of conditions in each link to obtain a high-purity product.

This is a new type of chemical compound. Due to its complex structure and newly released, there is no complete safety data.
Looking at the chemical name "N- {3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl} -6- [5- ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2-yl] quinazoline-4-aminobenzenesulfonate monohydrate (1:2:1) ", it can be seen that the structure is extremely complex. These new compounds, in terms of toxicology, ecological impact, stability and other safety-critical aspects, are often due to the lack of research and lack of conclusion.
On top of toxicology, or potential harm to human cells and organs. However, due to insufficient research, such as whether it is carcinogenic, teratogenic, mutagenic, and whether it affects the nervous system and immune system, it is unknown. The route of exposure or inhalation, skin contact, and accidental ingestion are also difficult to evaluate.
In terms of ecological impact, after entering the environment, it may have an impact on water, soil, air and other media. On aquatic organisms, it may interfere with their physiological functions, reproduction and growth; on soil microbial communities, or cause structural and functional changes. However, there is currently no data to support specific effects.
In terms of stability, storage and transportation conditions are demanding. Factors such as temperature and humidity, light, pH, etc. may cause it to decompose, deteriorate, and even cause dangerous reactions. However, the appropriate conditions have not been precisely studied.
In summary, although the structure of this compound is novel, its safety properties are unknown. Follow-up comprehensive and in-depth research is required to clarify the safety risks and provide a solid basis for use and management.

There is a product called N- {3-chloro-4- [ (3-fluorobenzyl) oxy] phenyl} -6- [5 - ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2-yl] quinazoline-4-aminobenzenesulfonate monohydrate (1:2:1). Looking at its market prospects, it is actually intertwined by many factors.
From the perspective of the pharmaceutical field, this compound may have unique pharmacological activity. Today's pharmaceutical research and development has a strong demand for new and targeted drugs. If this substance is studied in depth and proven to be effective in the treatment of specific diseases, such as tumors, cardiovascular and cerebrovascular diseases, its market potential will be limitless. Due to the large number of patients with such diseases and the need for refined treatment methods, once this substance is approved as a drug, it will be able to occupy a place in the market.
Looking at the chemical industry, the demand for special chemicals in fine chemicals is also growing. This compound has a complex structure and can be used as an intermediate to derive more high-value-added fine chemicals. With the advancement of chemical technology, the optimization of its synthesis process may increase production and reduce costs, thereby expanding its application scope in the chemical market.
However, its market prospects are not entirely bright. During the research and development process, it needs to go through rigorous clinical trials to prove its safety and effectiveness. This process is time-consuming and costly. In case of setbacks, the R & D process may be stalled and the market launch will be delayed. And the market competition is fierce. Similar or alternative products continue to emerge. If they fail to demonstrate their advantages in terms of performance and price, it may be difficult to gain a firm foothold in the market.
In summary, N- {3 -chloro-4- [ (3 -fluorobenzyl) oxy] phenyl} -6- [5- ({[2 - (methylsulfonyl) ethyl] amino} methyl) furan-2 - yl] quinazoline-4 -aminobenzenesulfonate monohydrate (1:2:1) has addressable market opportunities, but also faces many challenges. Only by grasping opportunities and responding to challenges can we seek development in the market.